† Surrogate for Norovirus, actual strain tested was Feline Calicivirus, ATCC VR-782, Strain F-9
*Human Coronavirus 229 is not SARS-CoV-2
Please note that testing the reduction rate of SARS-Cov-2 with GPS’ NPBI is an evolving process and additional testing is anticipated to be conducted
in the future. While GPS is not registered with the EPA as a surface disinfectant, this testing demonstrates GPS’ performance on surfaces.

Airius and Global Plasma Solutions (GPS) uses multiple data points to formulate performance validation statements. NPBI technology is used in a wide range of applications across diverse environmental conditions. Since locations will vary, clients should evaluate their individual application and environmental conditions when making an assessment regarding the technology’s potential benefits.

The use of this technology is not intended to take the place of reasonable precautions to prevent the transmission of pathogens. It is important to
comply with all applicable public health laws and guidelines issued by federal, state, and local governments and health authorities as well as official
guidance published by the Centers for Disease Control and Prevention (CDC), including but not limited to social distancing, hand hygiene, cough
etiquette, and the use of face masks.

All technical information and advice given here are based on GPS previous experiences and/or test results. Airius gives this information to the best
of its knowledge but assumes no legal responsibility. Customers are asked to check the suitability and usability in the specific application, since the
performance of the product can only be judged when all necessary operating data are available. The above information is subject to change.
NPBI® is a registered trademark of Global Plasma Solutions, Inc.